ResMed (NYSE: RMD) stock analysis — AirSense 11 platform, Philips recall windfall locked in, GLP-1 impact with real adherence data, Brightree/MatrixCare SaaS margin lift. TTM revenue $5.54B, FCF $1.75B. Bull case, bear case, and where we stand.
WBA Walgreens Boots Alliance stock analysis for 2026. Dividend cut context, VillageMD restructuring, PBM margin pressure, CVS competition, debt management, and bull/base/bear scenarios for dividend investors considering recovery plays.
Merck (MRK) 2026 stock analysis: Keytruda's 2028 patent cliff, Winrevair growth, $112.30 price, 3% dividend, analyst targets, and US investor tax strategy.
Pfizer (PFE) 2026 stock analysis: $26.48 price, 6.5% dividend yield, Seagen pipeline, patent cliff risks, and 12-month price targets for US investors.